Does the media refer more to CELU or VRCA?

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.72 indicating that Celularity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CELU or PYXS?

In the previous week, Celularity and Celularity both had 2 articles in the media. Pyxis Oncology's average media sentiment score of 0.94 beat Celularity's score of 0.93 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BMEA or CELU more profitable?

Biomea Fusion has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Celularity -345.45% N/A -77.94%

Does the media prefer BMEA or CELU?

In the previous week, Biomea Fusion and Biomea Fusion both had 2 articles in the media. Celularity's average media sentiment score of 0.93 beat Biomea Fusion's score of 0.62 indicating that Celularity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CELU or ONCY?

In the previous week, Oncolytics Biotech had 14 more articles in the media than Celularity. MarketBeat recorded 16 mentions for Oncolytics Biotech and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Oncolytics Biotech's score of -0.57 indicating that Celularity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts rate ICCC or CELU?

Celularity has a consensus target price of $6.00, suggesting a potential upside of 468.72%. Given Celularity's stronger consensus rating and higher possible upside, analysts plainly believe Celularity is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, ICCC or CELU?

ImmuCell has higher revenue and earnings than Celularity. ImmuCell is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.17 -$1.04M -$0.06 N/A Celularity $26.55M 1.15 -$91.72M -$3.33 N/A

Is ICCC or CELU more profitable?

ImmuCell has a net margin of -1.82% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat ImmuCell's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% Celularity -345.45% N/A -77.94%

Celularity (CELU) Competitors

$1.06 -0.02 (-1.40%)

As of 01:59 PM Eastern

Compare

CELU vs. VRCA, PYXS, BMEA, ONCY, and ICCC

Should you buy Celularity stock or one of its competitors? MarketBeat compares Celularity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celularity include Verrica Pharmaceuticals (VRCA), Pyxis Oncology (PYXS), Biomea Fusion (BMEA), Oncolytics Biotech (ONCY), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry.

How does Celularity compare to Verrica Pharmaceuticals?

Celularity (NASDAQ:CELU) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Celularity has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.72 indicating that Celularity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celularity presently has a consensus price target of $6.00, suggesting a potential upside of 468.72%. Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 144.93%. Given Celularity's higher probable upside, analysts clearly believe Celularity is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Verrica Pharmaceuticals has higher revenue and earnings than Celularity. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.15	-$91.72M	-$3.33	N/A
Verrica Pharmaceuticals	$37.16M	2.74	-$17.89M	-$1.03	N/A

Verrica Pharmaceuticals has a net margin of -47.97% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

19.0% of Celularity shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Verrica Pharmaceuticals beats Celularity on 12 of the 16 factors compared between the two stocks.

How does Celularity compare to Pyxis Oncology?

Celularity (NASDAQ:CELU) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Pyxis Oncology has lower revenue, but higher earnings than Celularity. Pyxis Oncology is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.15	-$91.72M	-$3.33	N/A
Pyxis Oncology	$13.86M	7.64	-$79.62M	-$1.31	N/A

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 468.72%. Pyxis Oncology has a consensus price target of $6.83, indicating a potential upside of 308.94%. Given Celularity's higher probable upside, equities analysts plainly believe Celularity is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Pyxis Oncology has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Pyxis Oncology	N/A	-135.60%	-85.00%

Celularity has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Celularity and Celularity both had 2 articles in the media. Pyxis Oncology's average media sentiment score of 0.94 beat Celularity's score of 0.93 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pyxis Oncology beats Celularity on 9 of the 15 factors compared between the two stocks.

How does Celularity compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market. Comparatively, Celularity has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Biomea Fusion has higher earnings, but lower revenue than Celularity. Biomea Fusion is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Celularity	$26.55M	1.15	-$91.72M	-$3.33	N/A

In the previous week, Biomea Fusion and Biomea Fusion both had 2 articles in the media. Celularity's average media sentiment score of 0.93 beat Biomea Fusion's score of 0.62 indicating that Celularity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomea Fusion presently has a consensus target price of $8.29, suggesting a potential upside of 489.73%. Celularity has a consensus target price of $6.00, suggesting a potential upside of 468.72%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biomea Fusion has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Celularity	-345.45%	N/A	-77.94%

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Biomea Fusion and Celularity tied by winning 7 of the 14 factors compared between the two stocks.

How does Celularity compare to Oncolytics Biotech?

Celularity (NASDAQ:CELU) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

19.0% of Celularity shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Celularity has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

In the previous week, Oncolytics Biotech had 14 more articles in the media than Celularity. MarketBeat recorded 16 mentions for Oncolytics Biotech and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Oncolytics Biotech's score of -0.57 indicating that Celularity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Celularity presently has a consensus target price of $6.00, indicating a potential upside of 468.72%. Oncolytics Biotech has a consensus target price of $8.50, indicating a potential upside of 788.19%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Oncolytics Biotech has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Oncolytics Biotech has lower revenue, but higher earnings than Celularity. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.15	-$91.72M	-$3.33	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Summary

Oncolytics Biotech beats Celularity on 9 of the 16 factors compared between the two stocks.

How does Celularity compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

ImmuCell has a net margin of -1.82% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Celularity	-345.45%	N/A	-77.94%

ImmuCell has higher revenue and earnings than Celularity. ImmuCell is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.17	-$1.04M	-$0.06	N/A
Celularity	$26.55M	1.15	-$91.72M	-$3.33	N/A

In the previous week, ImmuCell and ImmuCell both had 2 articles in the media. ImmuCell's average media sentiment score of 1.30 beat Celularity's score of 0.93 indicating that ImmuCell is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuCell	Positive
Celularity	Positive

ImmuCell has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Celularity has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 5.7% of ImmuCell shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Celularity has a consensus target price of $6.00, suggesting a potential upside of 468.72%. Given Celularity's stronger consensus rating and higher possible upside, analysts plainly believe Celularity is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ImmuCell beats Celularity on 8 of the 15 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELU vs. The Competition

Export

Metric	Celularity	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$29.24M	$3.37B	$6.39B	$12.59B
Dividend Yield	N/A	2.29%	2.69%	5.30%
P/E Ratio	-0.31	18.01	21.16	26.60
Price / Sales	1.15	183.22	512.63	95.38
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	-0.80	6.52	9.81	6.77
Net Income	-$91.72M	$24.15M	$3.56B	$337.23M
7 Day Performance	17.63%	-1.50%	0.31%	2.65%
1 Month Performance	10.24%	0.95%	4.68%	6.63%
1 Year Performance	-52.90%	51.23%	31.03%	37.91%

Celularity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELU Celularity	2.0203 of 5 stars	$1.06 -1.4%	$6.00 +468.7%	-51.1%	$29.24M	$26.55M	N/A	220	Gap Down
VRCA Verrica Pharmaceuticals	2.9997 of 5 stars	$6.02 -0.7%	$14.50 +140.9%	+17.8%	$103.42M	$35.58M	N/A	40	Analyst Downgrade
PYXS Pyxis Oncology	3.853 of 5 stars	$1.63 -16.8%	$6.83 +319.2%	+47.9%	$103.26M	$13.86M	N/A	60	Gap Up
BMEA Biomea Fusion	2.0151 of 5 stars	$1.41 -0.7%	$8.29 +487.6%	-3.5%	$101.94M	N/A	N/A	50	Analyst Downgrade
ONCY Oncolytics Biotech	3.5739 of 5 stars	$0.81 +0.1%	$8.50 +949.0%	+199.8%	$96.71M	N/A	N/A	30	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELU) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celularity (CELU) Competitors

CELU vs. VRCA, PYXS, BMEA, ONCY, and ICCC

How does Celularity compare to Verrica Pharmaceuticals?

Summary

How does Celularity compare to Pyxis Oncology?

Summary

How does Celularity compare to Biomea Fusion?

Summary

How does Celularity compare to Oncolytics Biotech?

Summary

How does Celularity compare to ImmuCell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celularity (CELU) Competitors

CELU vs. VRCA, PYXS, BMEA, ONCY, and ICCC

How does Celularity compare to Verrica Pharmaceuticals?

Which has more volatility and risk, CELU or VRCA?

Does the media refer more to CELU or VRCA?

Do analysts rate CELU or VRCA?

Which has stronger earnings & valuation, CELU or VRCA?

Is CELU or VRCA more profitable?

Do insiders and institutionals have more ownership in CELU or VRCA?

Summary

How does Celularity compare to Pyxis Oncology?

Which has better valuation and earnings, CELU or PYXS?

Do analysts recommend CELU or PYXS?

Is CELU or PYXS more profitable?

Which has more volatility and risk, CELU or PYXS?

Do institutionals & insiders believe in CELU or PYXS?

Does the media favor CELU or PYXS?

Summary

How does Celularity compare to Biomea Fusion?

Which has more volatility & risk, BMEA or CELU?

Which has higher valuation & earnings, BMEA or CELU?

Does the media prefer BMEA or CELU?

Do analysts rate BMEA or CELU?

Is BMEA or CELU more profitable?

Do institutionals & insiders have more ownership in BMEA or CELU?

Summary

How does Celularity compare to Oncolytics Biotech?

Do institutionals & insiders believe in CELU or ONCY?

Which has more risk and volatility, CELU or ONCY?

Does the media favor CELU or ONCY?

Do analysts prefer CELU or ONCY?

Is CELU or ONCY more profitable?

Which has better earnings & valuation, CELU or ONCY?

Summary

How does Celularity compare to ImmuCell?

Is ICCC or CELU more profitable?

Which has stronger earnings and valuation, ICCC or CELU?

Does the media refer more to ICCC or CELU?

Which has more risk and volatility, ICCC or CELU?

Do institutionals and insiders hold more shares of ICCC or CELU?

Do analysts rate ICCC or CELU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools